Colliers Securities analyst Barry Oxford maintained a Buy rating on Global Medical REIT (GMRE – Research Report) today and set a price target of $19.00. The company’s shares closed last Thursday at $17.07.
According to TipRanks.com, Oxford is a 4-star analyst with an average return of 16.6% and a 87.2% success rate. Oxford covers the Financial sector, focusing on stocks such as Alpine Income Property Trust Inc, Bluerock Residential Growth, and One Liberty Properties.
Global Medical REIT has an analyst consensus of Strong Buy, with a price target consensus of $17.25, a 2.7% upside from current levels. In a report released yesterday, BMO Capital also maintained a Buy rating on the stock with a $17.00 price target.
See the top stocks recommended by analysts >>
Based on Global Medical REIT’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $28.26 million and net profit of $4.01 million. In comparison, last year the company earned revenue of $22.06 million and had a net profit of $1.66 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Global Medical REIT, Inc. engages in the acquisition of purpose-built healthcare facilities and leasing of those properties to strong healthcare systems and physician groups. The company was founded on March 18, 2011 and is headquartered in Bethesda, MD.
Read More on GMRE:
